Literature DB >> 26719577

An HRE-Binding Py-Im Polyamide Impairs Hypoxic Signaling in Tumors.

Jerzy O Szablowski1, Jevgenij A Raskatov1, Peter B Dervan2.   

Abstract

Hypoxic gene expression contributes to the pathogenesis of many diseases, including organ fibrosis, age-related macular degeneration, and cancer. Hypoxia-inducible factor-1 (HIF1), a transcription factor central to the hypoxic gene expression, mediates multiple processes including neovascularization, cancer metastasis, and cell survival. Pyrrole-imidazole polyamide 1: has been shown to inhibit HIF1-mediated gene expression in cell culture but its activity in vivo was unknown. This study reports activity of polyamide 1: in subcutaneous tumors capable of mounting a hypoxic response and showing neovascularization. We show that 1: distributes into subcutaneous tumor xenografts and normal tissues, reduces the expression of proangiogenic and prometastatic factors, inhibits the formation of new tumor blood vessels, and suppresses tumor growth. Tumors treated with 1: show no increase in HIF1α and have reduced ability to adapt to the hypoxic conditions, as evidenced by increased apoptosis in HIF1α-positive regions and the increased proximity of necrotic regions to vasculature. Overall, these results show that a molecule designed to block the transcriptional activity of HIF1 has potent antitumor activity in vivo, consistent with partial inhibition of the tumor hypoxic response. Mol Cancer Ther; 15(4); 608-17. ©2015 AACR. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26719577      PMCID: PMC4873353          DOI: 10.1158/1535-7163.MCT-15-0719

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  50 in total

Review 1.  Exploiting tumour hypoxia in cancer treatment.

Authors:  J Martin Brown; William R Wilson
Journal:  Nat Rev Cancer       Date:  2004-06       Impact factor: 60.716

2.  Open source clustering software.

Authors:  M J L de Hoon; S Imoto; J Nolan; S Miyano
Journal:  Bioinformatics       Date:  2004-02-10       Impact factor: 6.937

Review 3.  Hypoxia in cancer: significance and impact on clinical outcome.

Authors:  Peter Vaupel; Arnulf Mayer
Journal:  Cancer Metastasis Rev       Date:  2007-06       Impact factor: 9.264

4.  Drug-target network.

Authors:  Muhammed A Yildirim; Kwang-Il Goh; Michael E Cusick; Albert-László Barabási; Marc Vidal
Journal:  Nat Biotechnol       Date:  2007-10       Impact factor: 54.908

5.  Lysyl oxidase is essential for hypoxia-induced metastasis.

Authors:  Janine T Erler; Kevin L Bennewith; Monica Nicolau; Nadja Dornhöfer; Christina Kong; Quynh-Thu Le; Jen-Tsan Ashley Chi; Stefanie S Jeffrey; Amato J Giaccia
Journal:  Nature       Date:  2006-04-27       Impact factor: 49.962

Review 6.  Patient-derived tumour xenografts as models for oncology drug development.

Authors:  John J Tentler; Aik Choon Tan; Colin D Weekes; Antonio Jimeno; Stephen Leong; Todd M Pitts; John J Arcaroli; Wells A Messersmith; S Gail Eckhardt
Journal:  Nat Rev Clin Oncol       Date:  2012-04-17       Impact factor: 66.675

7.  In vivo modulation of hypoxia-inducible signaling by topographical helix mimetics.

Authors:  Brooke Bullock Lao; Ivan Grishagin; Hanah Mesallati; Thomas F Brewer; Bogdan Z Olenyuk; Paramjit S Arora
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-12       Impact factor: 11.205

Review 8.  Promiscuous drugs compared to selective drugs (promiscuity can be a virtue).

Authors:  Simon K Mencher; Long G Wang
Journal:  BMC Clin Pharmacol       Date:  2005-04-26

Review 9.  Development of HIF-1 inhibitors for cancer therapy.

Authors:  Barbara Onnis; Annamaria Rapisarda; Giovanni Melillo
Journal:  J Cell Mol Med       Date:  2009-08-08       Impact factor: 5.310

10.  Replication stress by Py-Im polyamides induces a non-canonical ATR-dependent checkpoint response.

Authors:  Thomas F Martínez; John W Phillips; Kenneth K Karanja; Piotr Polaczek; Chieh-Mei Wang; Benjamin C Li; Judith L Campbell; Peter B Dervan
Journal:  Nucleic Acids Res       Date:  2014-09-23       Impact factor: 16.971

View more
  5 in total

Review 1.  The past and presence of gene targeting: from chemicals and DNA via proteins to RNA.

Authors:  T M Geel; M H J Ruiters; R H Cool; L Halby; D C Voshart; L Andrade Ruiz; K E Niezen-Koning; P B Arimondo; M G Rots
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2018-06-05       Impact factor: 6.237

2.  Synthetic genome readers target clustered binding sites across diverse chromatin states.

Authors:  Graham S Erwin; Matthew P Grieshop; Devesh Bhimsaria; Truman J Do; José A Rodríguez-Martínez; Charu Mehta; Kanika Khanna; Scott A Swanson; Ron Stewart; James A Thomson; Parameswaran Ramanathan; Aseem Z Ansari
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-08       Impact factor: 11.205

3.  Restoration of the prolyl-hydroxylase domain protein-3 oxygen-sensing mechanism is responsible for regulation of HIF2α expression and induction of sensitivity of myeloma cells to hypoxia-mediated apoptosis.

Authors:  Gilberto Gastelum; Aleksandra Poteshkina; Mysore Veena; Edgar Artiga; Geraldine Weckstein; Patrick Frost
Journal:  PLoS One       Date:  2017-12-05       Impact factor: 3.240

Review 4.  Targeting Transcription Factors for Cancer Treatment.

Authors:  Mélanie Lambert; Samy Jambon; Sabine Depauw; Marie-Hélène David-Cordonnier
Journal:  Molecules       Date:  2018-06-19       Impact factor: 4.411

Review 5.  The Road Not Taken with Pyrrole-Imidazole Polyamides: Off-Target Effects and Genomic Binding.

Authors:  Jason Lin; Hiroki Nagase
Journal:  Biomolecules       Date:  2020-04-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.